A synthetic calcium phosphate-based biomedical material comprising gadolinium. The material may comprises a compound having the general chemical formula: Ca.sub.10yGd.sub.y(PO.sub.4).sub.6x(SiO.sub.4)x(OH).sub.2c+y where 0<x<1.3 and 0<y<1.3.

A composition for imaging a cell includes a first imaging probe and a second imaging probe that include respectively a first reporter moiety and a second reporter moiety. The first reporter moiety and the second reporter moiety form a signaling complex that produces a detectable signal when the first imaging probe and second imaging probe complex with first and second biomarkers of the cell.

The present invention provides compounds and a method for the targeted delivery of Mitochondrial Angiotensin Receptor Blockers (MARBs) to the Mitochondrial Angiotensin System (MAS) for the treatment of diseases caused by angiotensin-related mitochondrial dysfunction. The compounds include a mitochondrial targeting signal, a residue of a drug molecule, a functional moiety, and a scaffold moiety.

The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.

An edible negative contrast agent for CT imaging of the gastrointestinal tract intended for oral intake. The contrast agent is a fluid, aqueous foam displaying a CT density contrast value in the range 300 to 800 HU and having a consistency of 7 to 12 cm as measured with Bostwick consistometer. The contrast agent comprises an aqueous continuous liquid phase having a pH of 6.5 to 8.0 and gas bubbles dispersed in the continuous aqueous liquid phase. The aqueous continuous liquid phase comprises a surfactant, the surfactant being a protein, a hydrocolloid acting as foam stabilizer, a buffering agent, and water.

Provided herein are nanoparticle compositions (e.g., nanoparticle compositions comprising high atomic number ions) that are useful for imaging diseases in a subject as well as radiosensitizing a disease in a subject (e.g., radiosensitizing a cancer in the subject). Methods of imaging a subject, methods of treating cancer, and processes of preparing the nanoparticle compositions are also provided.

3D cine MR angiography systems and methods are disclosed for use during the steady state intravascular distribution phase of ferumoxytol. The 3D cine MRA technique enables improved delineation of cardiac anatomy in pediatric patients undergoing cardiovascular MRI.

The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.

The present invention relates to a method for incorporating dye and/or nanoparticles into polymer films and into electrospun polymeric nanofibers, and, more specifically, to a method for electrospinning a molecularly homogenous solution of dye (and/or nanoparticles) and polymer dissolved in a mutual solvent leading to uniform distribution of dye across the cross-section of each constituent fiber and to resulting nanofibers with the dye/nanoparticles incorporated therein.

An aqueous approach to synthesize capped SnS quantum dots (QDs) followed by optional capping molecule extension by attaching one or more extending molecules to the capping molecule via peptide bond formation at elevated temperature. The capped SnS QDs may have a capping molecule:Sn:S molar ratio of 16:3:1 to 16:12:1. A suspension of SnS QDs was heat-treated at 200 C. for 0.5-4 hrs. The obtained SnS QDs showed an NIR emission peak at 820-835 nm with an excitation wavelength at 690 nm. The as synthesized SnS QDs were found to have high positive zeta potential of 30 mV and thus were toxic to cells. By neutralizing the SnS QDs the cytotoxicity was reduced to an accepted level. The heat-treatment step can be obviated by adding a glycerol solution containing S.sup.2 anions and capping molecule to a glycerol solution of Sn.sup.2+ ions.